EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Finerenone as a Third-Line Therapy for Persistent Proteinuria in Diabetic Kidney Transplant Recipients

Carmine Secondulfo iD, Dora Russo, Nicoletta Vecchione iD, Gianmarco Minelli iD, Luca Apicella, Candida Iacuzzo, Chiara Crescenzo, Maristella Minco, Anna Sannino, Gennaro Clemente, Antonio Pisani, Massimo Cirillo iD und 1 weitere

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27114832 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Carmine Secondulfo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, 84081 Baronissi, Italy. Hauptthemen laut MEDLINE: Kidney Transplantation, Proteinuria, Mineralocorticoid Receptor Antagonists, Diabetic Nephropathies. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Proteinuria is a strong predictor of graft failure in kidney transplant recipients (KTRs). While non-steroidal mineralocorticoid receptor antagonists (NS-MRAs), particularly finerenone, have demonstrated renoprotective benefits in chronic kidney disease, KTRs were excluded from pivotal trials. Evidence on finerenone’s safety and antiproteinuric effects in this population remains limited. This retrospective observational study evaluated 13 diabetic KTRs with persistent proteinuria despite optimized renin–angiotensin system blockade and sodium–glucose cotransporter 2 inhibitor therapy. Finerenone (10 mg/day) was added to standard care. Clinical and laboratory parameters, including estimated glomerular filtration rate (eGFR), serum electrolytes, total proteinuria, albuminuria, and their creatinine ratios, were assessed at baseline, 3 months, and 6 months. Safety outcomes focused on hyperkalemia and eGFR. Finerenone was discontinued in one patient due to hyperkalemia. In the remaining 12, 24-h proteinuria and urinary protein-to-creatinine ratio declined at 3 months and stabilized by 6 months. Conversely, no statistically significant changes were observed in albuminuria or the albumin-to-creatinine ratio. No clinically relevant changes occurred in eGFR, blood pressure, body weight, or serum electrolytes. This is the first study assessing finerenone in diabetic KTRs. Finerenone was well tolerated, was associated with an early reduction in proteinuria, and showed no adverse effects on graft function. These findings provide novel insights into the safety and potential role of finerenone in kidney transplant recipients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationProteinuriaMineralocorticoid Receptor AntagonistsDiabetic NephropathiesHumansFemaleMaleMiddle AgedGlomerular Filtration RateRetrospective StudiesAgedTransplant RecipientsAdultNaphthyridines

Stichwörter der Autor:innen

albuminuriadiabetesfinerenonekidney transplantproteinuria

Substanzen

finerenoneMineralocorticoid Receptor AntagonistsNaphthyridines

Autor:innen und Institutionen

  • Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, 84081 Baronissi, Italy.
  • Department of Public Health, University of Naples "Federico II", 80131 Naples, Italy.
  • Unit of Nephrology, Dialysis and Transplantation, University Hospital of Salerno "San Giovanni di Dio e Ruggi d'Aragona", 84131 Salerno, Italy.
  • Unit of Diabetology and Nutrition, University Hospital of Salerno "San Giovanni di Dio e Ruggi d'Aragona", 84131 Salerno, Italy.

ORCID-Profile: Carmine Secondulfo, Nicoletta Vecchione, Gianmarco Minelli, Massimo Cirillo

Zitieren

APA

Secondulfo, C., Russo, D., Vecchione, N., Minelli, G., Apicella, L., Iacuzzo, C., Crescenzo, C., Minco, M., Sannino, A., Clemente, G., Pisani, A., Cirillo, M., & Bilancio, G. (2026). Finerenone as a Third-Line Therapy for Persistent Proteinuria in Diabetic Kidney Transplant Recipients. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27114832

Vancouver

Secondulfo C, Russo D, Vecchione N, Minelli G, Apicella L, Iacuzzo C, et al. Finerenone as a Third-Line Therapy for Persistent Proteinuria in Diabetic Kidney Transplant Recipients. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27114832

BibTeX
@article{Secondulfo2026,
  author = {Secondulfo, Carmine and Russo, Dora and Vecchione, Nicoletta and Minelli, Gianmarco and Apicella, Luca and Iacuzzo, Candida and Crescenzo, Chiara and Minco, Maristella and Sannino, Anna and Clemente, Gennaro and Pisani, Antonio and Cirillo, Massimo and Bilancio, Giancarlo},
  title = {Finerenone as a Third-Line Therapy for Persistent Proteinuria in Diabetic Kidney Transplant Recipients},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27114832}
}
Kostenlos starten →